Constellation Pharmaceuticals, Inc. (CNST): Price and Financial Metrics


Constellation Pharmaceuticals, Inc. (CNST)

Today's Latest Price: $35.53 USD

1.93 (5.74%)

Updated May 29 4:00pm

Add CNST to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 214 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

CNST Daily Price Range
CNST 52-Week Price Range

CNST Stock Price Chart More Charts


CNST Price/Volume Stats

Current price $35.53 52-week high $59.49
Prev. close $33.60 52-week low $6.01
Day low $33.22 Volume 695,291
Day high $36.00 Avg. volume 413,576
50-day MA $35.92 Dividend yield N/A
200-day MA $28.88 Market Cap 1.49B

Constellation Pharmaceuticals, Inc. (CNST) Company Bio


Constellation Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing therapeutics that address serious unmet medical needs in patients with cancers associated with abnormal gene expression or drug resistance. The company’s lead product candidate CPI-1205 that is in Phase Ib/II clinical trials for the treatment of metastatic castration-resistant prostate cancer in combination with androgen receptor signaling inhibitors, as well as for the treatment of solid tumors in combination with immune checkpoint inhibitors. It is also developing CPI-0209, which is in preclinical trials for the treatment of solid tumors and/or hematological malignancies; and CPI-0610 that is in Phase II clinical trials for the treatment of patients with myelofibrosis in combination with ruxolitinib. The company was formerly known as Epigenetix, Inc. and changed its name to Constellation Pharmaceuticals, Inc. in March 2008. The company was founded in 2008 and is based in Cambridge, Massachusetts.


CNST Latest News Stream


Event/TimeNews Detail
Loading, please wait...

CNST Latest Social Stream


Loading social stream, please wait...

View Full CNST Social Stream

Latest CNST News From Around the Web

Below are the latest news stories about Constellation Pharmaceuticals Inc that investors may wish to consider to help them evaluate CNST as an investment opportunity.

Constellation Pharmaceuticals to Participate in Investor Conference

CAMBRIDGE, Mass., May 29, 2020 -- Constellation Pharmaceuticals, Inc. (Nasdaq: CNST), a clinical-stage biopharmaceutical company using its expertise in epigenetics to.

Yahoo | May 29, 2020

Constellation Pharmaceuticals to Host Analyst / Investor Event to Discuss Update of MANIFEST Clinical Trial for CPI-0610

CAMBRIDGE, Mass., May 28, 2020 -- Constellation Pharmaceuticals, Inc. (Nasdaq: CNST), a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover.

Yahoo | May 28, 2020

Constellation Pharmaceuticals, Inc. (CNST) Upgraded to Buy: What Does It Mean for the Stock?

Constellation Pharmaceuticals, Inc. (CNST) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Zacks Investment Research | May 25, 2020

Is Constellation (CNST) Stock a Solid Choice Right Now?

Constellation (CNST) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Yahoo | May 14, 2020

Constellation Pharmaceuticals Provides Update of Preliminary Data for CPI-0610 in Three EHA Abstracts

Continued high rate of SVR35 in 1L patients: 72% at 12 weeks and 67% at 24 weeksSVR35 responses and transfusion dependence conversion observed in 2L monotherapy patients.

Yahoo | May 14, 2020

Read More 'CNST' Stories Here

CNST Price Returns

1-mo -0.62%
3-mo -3.19%
6-mo -19.14%
1-year 312.18%
3-year N/A
5-year N/A
YTD -24.58%
2019 1,074.81%
2018 N/A
2017 N/A
2016 N/A
2015 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.7221 seconds.